/MEDP
MEDP Stock - Medpace Holdings, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$568.36+1.45%
+$8.15 (+1.45%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.79
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).46
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.63
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-1.8%upside
Target: $558.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MEDP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$562.68 – $574.04
TARGET (TP)$558.00
STOP LOSS$522.89
RISK/REWARD1:-0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.43
52W High$626.25
52W Low$250.05
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.11B | $1.89B | $1.46B | $1.14B | $925.92M |
| Gross Profit | $656.30M | $524.50M | $432.44M | $328.15M | $278.73M |
| Gross Margin | 31.1% | 27.8% | 29.6% | 28.7% | 30.1% |
| Operating Income | $446.87M | $336.82M | $278.70M | $198.62M | $167.04M |
| Net Income | $404.39M | $282.81M | $245.37M | $181.85M | $145.38M |
| Net Margin | 19.2% | 15.0% | 16.8% | 15.9% | 15.7% |
| EPS | $13.06 | $9.20 | $7.57 | $5.06 | $4.07 |
Company Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
35%
Hold / Neutral
10
50%
Sell / Underperform
3
15%
Analyst Consensus🔴 Bearish
7 Bullish13 Neutral/Bearish
Price Targets
$366
Average Target
↓ 35.6% Downside
Now
$142
Low
$366
Average
$600
High
Based on 21 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 13th 2025 | BMO Capital Markets | Initiation | Market Perform | $600 |
| October 2nd 2025 | Barclays | Downgrade | Underweight | $425 |
| September 3rd 2025 | Rothschild & Co Redburn | Downgrade | Neutral | $474 |
| July 29th 2025 | UBS | Downgrade | Sell | $305 |
| July 23rd 2025 | TD Cowen | Downgrade | Sell | $366 |
| June 24th 2025 | Barclays | Initiation | Equal Weight | $300 |
| April 22nd 2025 | William Blair | Downgrade | Market Perform | - |
| April 14th 2025 | TD Cowen | Downgrade | Hold | $328 |
| March 24th 2025 | Leerink Partners | Initiation | Market Perform | $330 |
| October 23rd 2024 | Robert W. Baird | Downgrade | Neutral | $349← $413 |
| October 14th 2024 | Redburn Atlantic | Initiation | Buy | - |
| September 27th 2024 | UBS | Downgrade | Neutral | $350← $420 |
| September 25th 2024 | Jefferies | Downgrade | Hold | $345← $415 |
| August 1st 2024 | Truist | Initiation | Hold | $415 |
| May 29th 2024 | TD Cowen | Initiation | Buy | $452 |
Earnings History & Surprises
MEDPBeat Rate
100%
Last 18 quarters
Avg Surprise
+16.0%
EPS vs Estimate
Beats / Misses
18/0
Last 12 quarters
Latest EPS
$3.86
Q4 2025
EPS Surprise History
Q1 24
+10.8%
$2.46vs$2.22
Q2 24
+29.6%
$3.20vs$2.47
Q3 24
+8.3%
$2.75vs$2.54
Q4 24
+8.3%
$3.01vs$2.78
Q1 25
+24.0%
$3.67vs$2.96
Q2 25
+19.9%
$3.67vs$3.06
Q3 25
+4.0%
$3.10vs$2.98
Q4 25
+10.3%
$3.86vs$3.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 20, 2026 | — | — | — | — |
Q1 2026 | Feb 9, 2026 | $4.18 | — | — | — |
Q4 2025 | Oct 22, 2025 | $3.50 | $3.86 | +10.3% | ✓ BEAT |
Q3 2025 | Jul 21, 2025 | $2.98 | $3.10 | +4.0% | ✓ BEAT |
Q2 2025 | Apr 21, 2025 | $3.06 | $3.67 | +19.9% | ✓ BEAT |
Q1 2025 | Feb 10, 2025 | $2.96 | $3.67 | +24.0% | ✓ BEAT |
Q4 2024 | Oct 21, 2024 | $2.78 | $3.01 | +8.3% | ✓ BEAT |
Q3 2024 | Jul 22, 2024 | $2.54 | $2.75 | +8.3% | ✓ BEAT |
Q2 2024 | Apr 22, 2024 | $2.47 | $3.20 | +29.6% | ✓ BEAT |
Q1 2024 | Feb 12, 2024 | $2.22 | $2.46 | +10.8% | ✓ BEAT |
Q4 2023 | Oct 23, 2023 | $2.05 | $2.22 | +8.3% | ✓ BEAT |
Q3 2023 | Jul 24, 2023 | $1.91 | $1.93 | +1.0% | ✓ BEAT |
Q2 2023 | Apr 24, 2023 | $1.80 | $2.27 | +26.1% | ✓ BEAT |
Q1 2023 | Feb 13, 2023 | $1.79 | $2.12 | +18.4% | ✓ BEAT |
Q4 2022 | Oct 24, 2022 | $1.47 | $2.05 | +39.5% | ✓ BEAT |
Q3 2022 | Jul 25, 2022 | $1.31 | $1.46 | +11.5% | ✓ BEAT |
Q2 2022 | Apr 25, 2022 | $1.26 | $1.69 | +34.1% | ✓ BEAT |
Q1 2022 | Feb 14, 2022 | $1.25 | $1.32 | +5.6% | ✓ BEAT |
Q4 2021 | Oct 25, 2021 | $1.07 | $1.29 | +20.6% | ✓ BEAT |
Q3 2021 | Jul 26, 2021 | $0.99 | $1.06 | +7.1% | ✓ BEAT |
Latest News
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $525
➖ NeutralBenzinga•Dec 15, 2025, 09:03 PM•Also:
BMO Capital Initiates Coverage On Medpace Hldgs with Market Perform Rating, Announces Price Target of $600
➖ NeutralBenzinga•Nov 13, 2025, 09:32 AM
TD Cowen Maintains Sell on Medpace Hldgs, Raises Price Target to $462
📉 NegativeBenzinga•Oct 24, 2025, 04:40 PM
Barclays Maintains Underweight on Medpace Hldgs, Raises Price Target to $485
➖ NeutralBenzinga•Oct 24, 2025, 01:46 PM•Also: ,
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $655
📈 PositiveBenzinga•Oct 24, 2025, 01:26 PM•Also:
Medpace Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
📈 PositiveBenzinga•Oct 23, 2025, 03:48 PM
Medpace surges on boost to 2025 guidance, Q3 beats
📈 PositiveSeeking Alpha•Oct 22, 2025, 09:40 PM
Medpace Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 guidance above estimates.
📈 PositiveBenzinga•Oct 22, 2025, 08:32 PM
Medpace Hldgs Raises FY2025 GAAP EPS Guidance from $13.76-$14.53 to $14.60-$14.86 vs $14.07 Est; Raises FY2025 Sales Guidance from $2.420B-$2.520B to $2.480B-$2.530B vs $2.464B Est
📈 PositiveBenzinga•Oct 22, 2025, 08:16 PM
Medpace Hldgs Q3 EPS $3.86 Beats $3.52 Estimate, Sales $659.903M Beat $640.997M Estimate
📈 PositiveBenzinga•Oct 22, 2025, 08:15 PM
Mizuho Maintains Outperform on Medpace Hldgs, Raises Price Target to $575
📈 PositiveBenzinga•Oct 17, 2025, 01:24 PM
Barclays Downgrades Medpace Hldgs to Underweight, Lowers Price Target to $425
📉 NegativeBenzinga•Oct 2, 2025, 11:28 AM•Also:
Jefferies Maintains Hold on Medpace Hldgs, Raises Price Target to $450
➖ NeutralBenzinga•Sep 9, 2025, 11:06 AM
Rothschild & Co Downgrades Medpace Hldgs to Neutral, Raises Price Target to $474
➖ NeutralBenzinga•Sep 3, 2025, 03:19 PM•Also:
Iqvia, Medpace send CRO peers higher after Q2 beats
📈 PositiveSeeking Alpha•Jul 22, 2025, 12:58 PM•Also:
Medpace surges 45% following earnings beats, 2025 guidance updates
📈 PositiveSeeking Alpha•Jul 22, 2025, 02:17 AM
Medpace drops despite Q1 beat amid disappointing performance metrics
📉 NegativeSeeking Alpha•Apr 22, 2025, 03:23 PM
Medpace GAAP EPS of $3.20 beats by $0.14, revenue of $558.6M beats by $31.45M
📈 PositiveSeeking Alpha•Apr 21, 2025, 08:18 PM
Frequently Asked Questions about MEDP
What is MEDP's current stock price?
Medpace Holdings, Inc. (MEDP) is currently trading at $568.36 per share. The stock has moved +1.45% today.
What is the analyst price target for MEDP?
The average analyst price target for MEDP is $558.00, based on 1 analyst.
What sector is Medpace Holdings, Inc. in?
Medpace Holdings, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is MEDP's market cap?
Medpace Holdings, Inc. has a market capitalization of $16.01 billion, making it a large-cap company.
Does MEDP pay dividends?
No, Medpace Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCNC
Centene Corporation
$39.03
Mkt Cap: $19.2B
DGX
Quest Diagnostics Incorporated
$176.06
Mkt Cap: $19.7B
HOLX
Hologic, Inc.
$74.95
Mkt Cap: $16.7B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
ILMN
Illumina, Inc.
$134.78
Mkt Cap: $20.6B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
TEM
Tempus AI, Inc.
$64.46
Mkt Cap: $11.1B
THC
Tenet Healthcare Corporation
$196.33
Mkt Cap: $17.3B
WAT
Waters Corporation
$378.03
Mkt Cap: $22.5B
WST
West Pharmaceutical Services, Inc.
$272.54
Mkt Cap: $19.6B
Explore stocks similar to MEDP for comparison